China’s National Medical Products Administration (NMPA) has accepted Mabwell’s Investigational New Drug (IND) application for 6MW5311, a bispecific antibody targeting LILRB4/CD3. This marks the first global regulatory acceptance for this novel T-cell engager therapy designed to treat certain hematologic malignancies.
The Shanghai-based biopharma company specializes in innovative antibody therapies, with 6MW5311 representing their most advanced bispecific candidate. Analysts note this development positions Mabwell among a select group of Chinese biotechs advancing next-generation immunotherapies.
“Acceptance of the IND application demonstrates regulatory confidence in the preclinical data package,” said a biotechnology analyst familiar with the filing who requested anonymity due to professional restrictions. The candidate now progresses to Phase 1 clinical trials in China.
Industry observers suggest successful development could help address unmet needs in acute myeloid leukemia (AML) and other LILRB4-expressing cancers. However, some researchers caution that bispecific antibodies present unique safety challenges that will require careful clinical evaluation.